Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
12 December 2020 |
Main ID: |
NCT03784547 |
Date of registration:
|
13/12/2018 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM
RWD_ocre |
Scientific title:
|
Real-world Patient Profile and Treatment Persistence of Ocrelizumab in Multiple Sclerosis: A Retrospective Analysis in Latin America |
Date of first enrolment:
|
February 1, 2019 |
Target sample size:
|
100 |
Recruitment status: |
Recruiting |
URL:
|
https://clinicaltrials.gov/show/NCT03784547 |
Study type:
|
Observational |
Study design:
|
|
Phase:
|
|
|
Countries of recruitment
|
Argentina
| | | | | | | |
Contacts
|
Name:
|
Juan I Rojas, MD |
Address:
|
|
Telephone:
|
+5491169001957 |
Email:
|
juan.rojas@hiba.org.ar |
Affiliation:
|
|
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- multiple sclerosis patients that received ocrelizumab
Exclusion Criteria:
-
Age minimum:
N/A
Age maximum:
N/A
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Multiple Sclerosis
|
Intervention(s)
|
Drug: Ocrelizumab
|
Primary Outcome(s)
|
Proportion of patients discontinuing the treatment with ocrelizumab in the last 12 months after inclusion
[Time Frame: 12 months]
|
Multiple sclerosis phenotype
[Time Frame: 12 months]
|
Secondary Outcome(s)
|
Gender
[Time Frame: 12 months]
|
Age at study entry
[Time Frame: 12 months]
|
Secondary ID(s)
|
RWD_Ocrelizumab LATAM
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|